Zelira Financial Statements From 2010 to 2025
| ZLDAF Stock | USD 0.23 0.00 0.00% |
Check Zelira Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zelira Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Zelira financial statements analysis is a perfect complement when working with Zelira Therapeutics Valuation or Volatility modules.
Zelira |
Zelira Therapeutics Limited OTC Stock Shares Owned By Insiders Analysis
Zelira Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Zelira Therapeutics Shares Owned By Insiders | 44.26 % |
Most of Zelira Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zelira Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 44.26% of Zelira Therapeutics Limited are shares owned by insiders. This is 191.57% higher than that of the Healthcare sector and 212.13% higher than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Zelira Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zelira Therapeutics's current stock value. Our valuation model uses many indicators to compare Zelira Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zelira Therapeutics competition to find correlations between indicators driving Zelira Therapeutics's intrinsic value. More Info.Zelira Therapeutics Limited is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zelira Therapeutics' earnings, one of the primary drivers of an investment's value.About Zelira Therapeutics Financial Statements
Zelira Therapeutics stakeholders use historical fundamental indicators, such as Zelira Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Zelira Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zelira Therapeutics' assets and liabilities are reflected in the revenues and expenses on Zelira Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zelira Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia. Zelda Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Zelira OTC Stock
Zelira Therapeutics financial ratios help investors to determine whether Zelira OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zelira with respect to the benefits of owning Zelira Therapeutics security.